2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2961

Antiphospoholipid Antibodies in Adult IgA Vasculitis: Aps/PT Antibodies As a Potential Marker of Renal Involvement?

Vasculitis - Poster III: Rarer Vasculitides

9:00AM-11:00AM: Abstract Number: 2263

Apolipoprotein E Regulates Inflammation and Joint Destruction during Antigen-Induced Arthritis (AIA)

Innate Immunity and Rheumatic Disease - Poster II

9:00AM-11:00AM: Abstract Number: 2865

Apoptotic Microparticles, but Not Exosomes, Induce an Inflammatory Response in Synoviocytes

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 2846

Application of a Novel Anti-Nuclear Antibody Multiplex Test Using Finger Stick and Venous Whole Blood in a Rheumatology Clinic – Demonstration of Feasibility

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2703

Apremilast May Improve Atherosclerosis By Promoting Cholesterol Efflux and Inhibiting Foam Cell Formation in Atherosclerotic Plaques

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster II

9:00AM-11:00AM: Abstract Number: 2533

Are There Differences in Baseline Comorbidities Between Rheumatoid Arthritis Patients Treated with Abatacept and Those Treated with Tumor Necrosis Factor Inhibitors?

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2840

Are There Genetic Predispositions to Diffuse Large B-Cell Lymphoma (DLBCL) in Systemic Lupus (SLE)?

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2568

ARL15 expressed By Rheumatoid Arthritis Synovial Fibroblasts Regulates IL6 and Plays a Role in Apoptosis and Hypoxia

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster III

9:00AM-11:00AM: Abstract Number: 2191

Arthritis As a Potential Barrier to Physical Activity Among Adults with Depression – United States, Behavioral Risk Factor Surveillance System, 2013

Epidemiology and Public Health - ARHP Poster

9:00AM-11:00AM: Abstract Number: 2966

Assessment of Damage in Behcet’s Disease: Do We Need a Specific Damage Index?

Vasculitis - Poster III: Rarer Vasculitides

9:00AM-11:00AM: Abstract Number: 2760

Assessment of Inflammatory Back Pain and Axial Spondyloarthritis in Brazil

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2507

Assessment of Liver Fibrosis Using Transient Elastography in Patients with Rheumatoid Arthritis Exposed to Long Term Methotrexate

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2468

Assessment of the American-English Version of the French FLARE in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2773

Assessment of the Static and Dynamic Balances in Psoriatic Arthritis (PsA) and Their Relations with Clinical, Radiological and Functional Parameters of Feet

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2188

Association Between Extent of Symptomatic Joint Involvement in Osteoarthritis and Comorbid Lung Disease in Patients Scheduled for Joint-Replacement Surgery

Epidemiology and Public Health - ARHP Poster

«Previous Page
1
…
3
4
5
6
7
…
69
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].